The Positron Emission Tomography (PET) market will grow from US$ 1.06 Billion in 2024 to US$ 1.51 Billion in 2033, at a Compound Annual Growth Rate (CAGR) of 4.02% from 2025-2033. Increased prevalence of chronic illnesses, technological advancements in imaging, and heightened demand for early and precise diagnostics drive growth. Increasing applications in oncology, neurology, and cardiology also drive worldwide market growth.
Globally, PET is predominantly applied to detect and monitor cancer and to evaluate blood flow and cardiac function in cardiology, and to investigate brain disorders like Alzheimer's disease, epilepsy, and Parkinson's disease in neurology. Its popularity increases because of rising demand for early and precise diagnostics, minimally invasive treatments, and customized treatment planning.
The increasing number of chronic diseases worldwide, advancements in hybrid imaging technology, and favorable healthcare programs are fuelling growth. PET's capability to facilitate improved clinical decision-making makes it a key diagnostic tool in contemporary medicine in both developed and developing economies.
Positron Emission Tomography Market Outlook
Positron Emission Tomography (PET) is a sophisticated medical imaging modality that employs radioactive tracers to image metabolic processes and identify abnormalities within the body. Through the detailed 3D images of tissue and organ function, PET scans enable doctors to detect disease in its initial stages, even before structural changes are evident on conventional imaging techniques. The method is often used in conjunction with CT or MRI scans for accurate diagnosis.Globally, PET is predominantly applied to detect and monitor cancer and to evaluate blood flow and cardiac function in cardiology, and to investigate brain disorders like Alzheimer's disease, epilepsy, and Parkinson's disease in neurology. Its popularity increases because of rising demand for early and precise diagnostics, minimally invasive treatments, and customized treatment planning.
The increasing number of chronic diseases worldwide, advancements in hybrid imaging technology, and favorable healthcare programs are fuelling growth. PET's capability to facilitate improved clinical decision-making makes it a key diagnostic tool in contemporary medicine in both developed and developing economies.
Growth Drivers in the Positron Emission Tomography Market
Rising Incidence of Chronic Diseases
The rising incidence of cancer, cardiovascular illnesses, and other types of neurological disorders has become a key growth driver in the positron emission tomography (PET) industry. Early diagnosis and accurate testing are critical in better managing these multifaceted health issues, and PET scans are unparalleled in imaging clarity compared to other diagnostic technologies. This new imaging technology allows physicians to image metabolic functions in real time, which enhances treatment decisions and ultimately patient outcomes. July 2024, Chronic kidney disease (CKD) impacts more than 35.5 million adults in the United States. The predominant causes of CKD in these individuals are diabetes and hypertension. Sadly, people are very much unaware of CKD; almost 9 out of 10 individuals suffering from the disease remain clueless. Even among severely affected CKD individuals, about 1 in 3 remains unaware of their condition.Advancements in Imaging Systems
Hybrid imaging modalities like PET/CT and PET/MRI are transforming the landscape of medical diagnostics. These new technologies bring together various forms of imaging to provide a broader picture of physiological functions. Combined with major developments in detector technology, these modalities have the ability to create extremely clean and crisp images. Consequently, they are greatly enhancing diagnostic accuracy and allowing healthcare professionals to make better-informed decisions. This innovation wave is driving higher adoption at hospitals and diagnostic imaging centers, improving patient care and outcomes. Sep 2024, GE HealthCare was granted FDA clearance for Flyrcado™ (flurpiridaz F 18) injection, a new PET MPI agent to detect coronary artery disease (CAD). Targeted toward patients with suspected or known CAD, Flyrcado provides superior diagnostic performance compared with SPECT MPI, the dominant nuclear cardiology test. It can be manufactured offsite and shipped as a ready-to-use dose, which can enhance access to PET MPI and diagnostic precision, most notably for women and patients with high BMI.Growing Applications in Personalized Medicine
With the healthcare environment increasingly moving towards precision and personalized medicine, there is a significant increase in the need for positron emission tomography (PET) imaging. This advanced imaging modality is vital in tracking therapy responses and optimal planning of treatment strategies in a patient-specific manner. Its unparalleled contribution towards validating whether therapies are working helps trigger worldwide market growth, promoting innovation and investment in this vital field of medical imaging. May 2022, Mediso Ltd has recently acquired Bartec Technologies Ltd, a UK-based specialist in supplying and supporting Nuclear Medicine and Molecular Imaging equipment and accessories.Challenges in the Positron Emission Tomography Market
High Cost of PET Equipment and Procedures
PET scanners, as precious diagnostic tools in contemporary medicine, are burdened by enormous financial costs that acutely restrict their availability, especially in developing countries. The explosive cost of radiopharmaceuticals and the high operation and maintenance costs of these advanced imaging machines form insurmountable hurdles for healthcare facilities. This pecuniary burden frequently inhibits the capacity of hospitals and clinics in resource-poor regions to provide modern medical imaging, thereby ultimately affecting patient care and outcome.Short Half-Life of Radioactive Tracers
Positron emission tomography (PET) scanning employs tracers with very short half-lives, which greatly restricts their potential for wider distribution. This reliance requires the close proximity of cyclotron facilities - where the tracers are manufactured - along with very efficient logistics operations to provide timely delivery. Consequently, this logistical difficulty presents considerable hindrances to universal access, especially in distant locations or areas of restricted resources, thus limiting the adoption and use of PET imaging technology in these areas.Full-Ring Positron Emission Tomography Scanners Market
Full-ring PET scanners lead the market because they are very sensitive and can deliver complete 3D images. They are applied extensively in oncology, cardiology, and neurology fields. Full-ring models provide faster imaging times as well as better detection efficiency than partial-ring models. Rising hospital investments, expanding research in molecular imaging, and hybrid integration with imaging systems are driving demand for full-ring PET scanners across the globe.Positron Emission Tomography Bismuth Germanium Oxide Market
BGO detectors find extensive applications in PET scanners due to their density and efficiency in detecting gamma-rays. While newer crystals such as LYSO are increasingly popular, BGO continues to be a trusted option for cost-saving PET solutions. The market enjoys increased installations in emerging nations and sustained demand for rugged and efficient detectors in oncology and neurology imaging applications.Cardiology Positron Emission Tomography Market
Cardiology PET imaging is growing with the capability to evaluate myocardial perfusion, blood flow, and early diagnosis of coronary artery disease. PET scans are increasingly being favored for the assessment of heart function in high-risk patients, guidance for interventions, and evaluation of therapy progress. The increasing cardiovascular disease burden worldwide and increasing use of hybrid PET/CT systems within cardiology departments are driving growth in this segment.Oncology Positron Emission Tomography Market
Oncology is the largest area for the PET market because detection and monitoring of cancer are still fundamental applications. PET scans facilitate early tumor detection, staging, and monitoring of therapy response to enhance treatment outcomes. With increased incidence of cancer and increasing applications in precision oncology, the demand for PET imaging is increasing internationally. Advances in radiopharmaceuticals and hybrid imaging modalities further reinforce its position in cancer treatment.United States Positron Emission Tomography Market
The U.S. dominates the worldwide PET market because of superior healthcare infrastructure, elevated cancer incidence, and swift uptake of hybrid imaging technology. The availability of prime manufacturers, robust reimbursement schemes, and extensive research in radiopharmaceuticals fuel market growth. Ongoing investments in molecular imaging and clinical trials further establish the U.S. as a top hub for PET technology development and uptake. July 2024, Positrigo, a Swiss medical imaging specialist for nuclear medicine, has gained FDA clearance for its NeuroLF® brain PET system. The highly portable device supports the diagnosis and monitoring of brain diseases like Alzheimer's, brain tumors, epilepsy, and Parkinson's disease.France Positron Emission Tomography Market
The PET market in France is supported by favorable government healthcare support and increasing focus on cancer and neurological diagnostics. Sophisticated hospitals and imaging centers in urban areas such as Paris and Lyon fuel the uptake of PET/CT systems. Interconnection with the European health network and investments in radiopharmaceutical production increase availability. Expanded application of PET in research, therapy monitoring, and early disease detection increases market growth. April 2025, Telix Pharmaceuticals reported that its prostate cancer imaging agent, Illuccix® (gallium-68 gozetotide injection), has been granted marketing authorization in France for the detection of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer.China Positron Emission Tomography Market
China is witnessing strong PET market expansion driven by increasing incidence of cancer, urbanization, and growing healthcare infrastructure. Investments in government-funded nuclear medicine centers and local radiopharmaceutical manufacturing are enhancing accessibility. The market is aided by increasing demand for sophisticated diagnostic technologies in first-tier cities, while ongoing penetration into second-tier cities drives long-term opportunities in the PET imaging market. Jan. 2022, Clario and XingImaging have deepened their collaboration to perform PET imaging clinical trials of new therapeutics in China.Brazil Positron Emission Tomography Market
Brazil's PET market is growing as a result of expanding awareness of the early detection of cancer and rising use of hybrid PET/CT imaging in urban hospital settings. Government and private investment in nuclear medicine equipment is enhancing diagnostic efficiencies. The market is challenged in terms of rural access but is aided by collaborations with global imaging firms and growing demand for cardiovascular and oncology imaging services.Saudi Arabia Positron Emission Tomography Market
Saudi Arabia's PET market is underpinned by Vision 2030-driven healthcare modernization, emphasizing cutting-edge diagnostic tools. Financed investments in specialty hospitals and nuclear medicine are boosting PET uptake for oncology and cardiology use. Market accessibility is being enhanced through partnerships with global imaging firms and increased radiopharmaceutical manufacturing facilities. Medical tourism growth and increasing prevalence of chronic diseases are further driving demand. December 2024, King Abdulaziz University has launched the first diagnostic service for Alzheimer's disease, using combined positron emission tomography and magnetic resonance imaging, namely PET/MRI.Market Segmentation
Product Type
- Full-Ring PET Scanners
- Partial-Ring PET Scanners
Detector Type
- Bismuth Germanium Oxide
- Lutetium Oxyorthosilicate
- Lutetium Fine Silicate
- Lutetium Yttrium Orthosilicate
- Gadolinium Oxyorthosilicate
Application
- Cardiology
- Neurology
- Oncology
- Others
End-User
- Hospitals and Clinics
- Diagnostic Centers
- Others
Country
North America
- United States
- Canada
Europe
- France
- Germany
- Italy
- Spain
- United Kingdom
- Belgium
- Netherlands
- Turkey
Asia Pacific
- China
- Japan
- India
- South Korea
- Thailand
- Malaysia
- Indonesia
- Australia
- New Zealand
Latin America
- Brazil
- Mexico
- Argentina
Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
All companies have been covered with 5 Viewpoints
- Overviews
- Key Person
- Recent Developments
- SWOT Analysis
- Revenue Analysis
Key Players Analysis
- Agfa Healthcare (Dedalus Group)
- GE Healthcare
- Koninklijke Philips NV
- Neusoft Medical Systems
- Positron Corporation
- Oncovision (Bruker)
- Mediso Medical Imaging Systems Ltd.
- Siemens Healthineers AG
- Segami Corporation
- Hitachi Ltd.
Table of Contents
1. Introduction3. Executive Summary12. Value Chain Analysis
2. Research & Methodology
4. Market Dynamics
5. Global Positron Emission Tomography Market
6. Market Share Analysis
7. Product Type
8. Detector Type
9. Application
10. End-User
11. Countries
13. Porter's Five Forces Analysis
14. SWOT Analysis
15. Pricing Benchmark Analysis
16. Key Players Analysis
Companies Mentioned
- Agfa Healthcare (Dedalus Group)
- GE Healthcare
- Koninklijke Philips NV
- Neusoft Medical Systems
- Positron Corporation
- Oncovision (Bruker)
- Mediso Medical Imaging Systems Ltd.
- Siemens Healthineers AG
- Segami Corporation
- Hitachi Ltd.
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | August 2025 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value ( USD | $ 1.06 Billion |
| Forecasted Market Value ( USD | $ 1.51 Billion |
| Compound Annual Growth Rate | 4.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
